News Allergan ‘not looking for big deals’ as growth slows Company will put its $27 billion to use, however
News Merck, Allergan named as potential bidders for Biogen Biogen vulnerable to takeover as chief executive steps down
News Lily gets FDA nod for SERD-CDK 4/6 combo in breast cancer Eli Lilly's imlunestrant (Inluriyo) for breast cancer has received a new FDA approval, in combination with CDK4/6 inhibitor abemaciclib (Verzenio).
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
